Claims for Patent: 6,165,993
✉ Email this page to a colleague
Summary for Patent: 6,165,993
Title: | DNA vaccines against rotavirus infections |
Abstract: | This invention relates to methods of eliciting an immune response and/or protective immunity in a vertebrate by introducing into the vertebrate a DNA vaccine which consists essentially of DNA encoding an antigen or antigens, e.g., capsid proteins or polypeptides, of rotavirus. The uptake of the DNA vaccine by a host vertebrate results in the expression of the capsid protein, thereby eliciting humoral or cell-mediated immune responses, or both, which can provide protection against infection and/or prevent clinically significant rotavirus-caused disease. In addition, the invention demonstrates that an internal viral antigen provides protective immunity in a host. The host can be any vertebrate, including birds, piglets, and humans. |
Inventor(s): | Herrmann; John E. (Northborough, MA), Robinson; Harriet L. (Southborough, MA), Fynan; Ellen F. (Sterling, MA) |
Assignee: | University of Massachusetts Medical Center (Worcester, MA) |
Application Number: | 09/233,813 |
Patent Claims: | 1. A method of eliciting an immune response against a rotavirus in a vertebrate, said method comprising administrating to the vertebrate a plasmid vector comprising one or
more isolated nucleotide sequences each encoding a rotavirus polypeptide selected from the group consisting of VP4, VP6, and VP7, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby
expression of said nucleotide sequences in one or more cells in the vertebrate elicits a humoral immune response, a cell-mediated immune response, or both, against the rotavirus.
2. A method of eliciting a protective immunity against a rotavirus infection in a vertebrate, said method comprising administering to the vertebrate a plasmid vector comprising one or more isolated nucleotide sequence each encoding a rotavirus polypeptide selected from the group consisting of VP4, VP6, and VP7, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby expression of said nucleotide sequences in one or more cells in the vertebrate elicits a humoral immune response, a cell-mediated immune response, or both against the rotavirus in the vertebrate, and whereby the vertebrate is protected from the disease caused by subsequent exposure to the rotavirus. 3. A method of claim 2, wherein the regulatory sequences are of nonretroviral origin. 4. A method of claim 2, wherein at least one of said regulatory sequences is the cytomegalovirus immediate-early enhancer promoter. 5. A method of claim 2, wherein at least one of said regulatory sequences is intron A. 6. A method of claim 2, wherein said rotavirus polypeptide is VP4. 7. A method of claim 2, wherein said rotavirus polypeptide is VP6. 8. A method of claim 2, wherein said rotavirus polypeptide is VP7. 9. A method of claim 2, wherein said vertebrate is a pig. 10. A method of claim 2, wherein said vertebrate is a human. 11. A method of claim 2, wherein the plasmid vector is administered to the vertebrate through a route of administration selected from the group consisting of inhalation, intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous. 12. A method of claim 2, wherein the plasmid vector is administered to the vertebrate by contacting the plasmid vector with a mucosal surface of the vertebrate. 13. A method of claim 2, wherein the plasmid vector is micorosphere encapsulated, and is administered to the vertebrate by contacting the microsphere-encapsulated plasmid vector with a mucosal surface of the vertebrate. 14. A method of claim 2, wherein the plasmid vector is coated onto gold beads for administration to the vertebrate by particle bombardment delivery. 15. A method of claim 14, wherein the gold beads are approximately 1 .mu.m to 2 .mu.m in diameter. 16. A method of claim 2, wherein the protective immunity is homologous, homotypic, heterotypic, or heterologous. 17. A method of claim 2, wherein the vertebrate is a mammal. |
Details for Patent 6,165,993
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2012-03-23 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2012-03-23 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2012-03-23 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.